US74907L3006 - ADR
QUOIN PHARMACEUTICALS LT-ADR
NASDAQ:QNRX (12/19/2024, 1:13:42 PM)
0.6
+0.04 (+7.14%)
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
QUOIN PHARMACEUTICALS LT-ADR
23 Hata'as Street
Kfar Saba
P: 97299741444
CEO: Shai Yarkoni
Employees: 4
Website: https://quoinpharma.com/
Wondering what's happening in Thursday's pre-market session? Find an overview in this article.
Groundbreaking ‘Whole Body’ Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have QRX003 applied twice daily...
Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant Improvement in Skin...
Top movers in Wednesday's after hours session
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant...
Here you can normally see the latest stock twits on QNRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: